- Conditions
- Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 51
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 185
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age Related Macular Degeneration, Pigment Epithelial Detachment
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Tennessee Retina
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,775 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Cystoid Macular Edema, Diabetic Macular Edema
- Interventions
- Intravitreal Aflibercept Injection
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Bakersfield, California • Santa Barbara, California
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Palmetto Retina Center, LLC
- Other
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Augusta, Georgia • Lincoln, Nebraska • West Columbia, South Carolina + 3 more
- Conditions
- Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
- Procedure · Drug
- Lead sponsor
- Retina Vitreous Associates of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Clearwater, Florida
- Conditions
- Uveal Melanoma
- Interventions
- Stereotactic Body Radiation Therapy, Ziv-Aflibercept
- Radiation · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetic Macular Edema, Cataract
- Interventions
- Bevacizumab, Ranibizumab, Aflibercept, Ozurdex
- Drug
- Lead sponsor
- Bay Area Retina Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Walnut Creek, California
- Conditions
- Proliferative Diabetic Retinopathy (PDR)
- Interventions
- Aflibercept 8mg
- Drug
- Lead sponsor
- Edward Wood, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Austin, Texas • Bellaire, Texas • San Antonio, Texas
- Conditions
- Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
- Interventions
- REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Winter Haven, Florida • Boston, Massachusetts + 2 more
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Aflibercept, Ranibizumab, Bevacizumab
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 331,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Macular Degeneration
- Interventions
- VEGF Trap Eye
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 33
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Aflibercept, Faricimab, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 44 more
- Conditions
- Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- Interventions
- EYE103, Aflibercept 2.0 mg
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 55
- States / cities
- Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Alflibercept
- Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Diabetic Macular Edema
- Interventions
- Ranibizumab 0.3 mg, Aflibercept 2.0 mg
- Drug
- Lead sponsor
- Arshad Khanani
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Retinal Hemangioma
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 18 Years and older · Male only
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Wet Macular Degeneration
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 671 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Campbell, California + 47 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- DE-120, Aflibercept
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
- Conditions
- Macular Degeneration
- Interventions
- NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
- Drug
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Intravitreal aflibercept injection, Placebo
- Drug
- Lead sponsor
- Jeffrey S Heier
- Other
- Eligibility
- Not listed
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Boston, Massachusetts • Edison, New Jersey + 1 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Ozurdex, Eylea
- Drug
- Lead sponsor
- Texas Retina Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Macular Edema Secondary to Central Retinal Vein Occlusion
- Interventions
- VEGF Trap-Eye 2.0mg, Sham
- Biological · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more